Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche
Executive Summary
Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained
You may also be interested in...
Roche Keeps Lifecycle Management In Motion For Oncology Portfolio
The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics
Roche Keeps Lifecycle Management In Motion For Oncology Portfolio
The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics
Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says
Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said